Kezdőlap・Részvénylista・Omeros Corp

Omeros Corp

Lezárt

SzektorEgészségügy

12.65 -2.32

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

12.55

Maximum

13.1

Fő mutatók
By Trading Economics
Bevétel	-35M 51M
Értékesítés	9.9M 9.9M
P/E Szektor átlag	11.018 68.51
Egy részvényre jutó nyereség	0.57
Profit margin	518.033
Munkavállalók	175
EBITDA	86M 57M

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+155.02% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 13.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-127M 909M
Előző nyitás	14.97
Előző zárás	12.65

Hangulat hírek alapján

By Acuity

59%

41%

280 / 340 Rangsor szerint Healthcare

Omeros Corp Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 5. 23:51 UTC

Omeros Corp shares are higher in after-market trading. Broader market sentiment is influenced by disappointing ADP employment data as investors await Non-Farm Payrolls.

2026. aug. 4. 23:02 UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

2026. aug. 3. 23:11 UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

2026. aug. 1. 00:01 UTC

Omeros Corp shares are higher in after-market trading, reaching a notable high and staying above the 20-day moving average. No specific news was identified.

2026. júl. 31. 23:41 UTC

Omeros Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

2026. júl. 30. 16:06 UTC

Omeros Corp shares are higher today, continuing a steady increase since Wednesday. The stock trades near the upper end of its one-month range.

2026. júl. 29. 18:58 UTC

Social Media

Omeros Corp is trading higher today, driven by positive social media sentiment despite broader weakness in the XBI sector. Market volume remains unusually high.

2026. júl. 28. 19:16 UTC

Social Media

Omeros Corp shares are lower today after earlier declines, amid social media discussions highlighting reduced competition following AstraZeneca's failed trial related to HSCT-TMA.

2026. júl. 27. 21:01 UTC

Omeros Corp shares are higher in after-market hours, following a broader market trend amid easing geopolitical tensions and declining oil prices.

2026. júl. 24. 19:26 UTC

Omeros Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the movement.

2026. júl. 22. 18:46 UTC

Omeros Corp shares are higher today, continuing an upward trend since Tuesday. Broader market dynamics are influenced by rising crude oil prices amid geopolitical tensions.

2026. júl. 21. 23:06 UTC

Omeros Corp. shares traded roughly flat in after-market hours. The stock remains below its 20-day moving average, marking three consecutive lower daily closes.

2026. júl. 20. 19:26 UTC

Omeros Corp shares are higher today, despite an earlier pullback. The stock has stabilized since Friday's close within its one-month trading range.

Társak összehasonlítása

Árváltozás

Omeros Corp Előrejelzés

Célár

By TipRanks

155.02% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 33 USD 155.02%

Magas 33 USD

Alacsony 33 USD

2 Wall Street elemző 12 hónapos célárain alapulva a(z)Omeros Corp termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

2 ratings

Vétel

Tartás

Eladás

2 Wall Street elemző célárain alapulva a(z)Omeros Corp termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

280 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.